RxDoctor Payments Data

Kasturi Etukuru, MD

Internal Medicine · Staten Island, NYNPI 1912117300

Payments from drug & device makers

$1,174in general payments, 2019–2025

Across 62 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$586
  • Johnson & Johnson$249
  • Bioxcel Therapeutics, Inc.$115
  • Pfizer$99
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$43
  • Gilead$29
  • plus $52 from 2 others

What the payments were for

  • Food & beverage$1,174100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,174 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$346,884
Medicare patients
932
Services billed
3,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban43$16,798
Cefpodoxime Proxetil43$817
Albuterol Sulfate HfaAlbuterol Sulfate34$748
Pantoprazole Sodium82$741
CefuroximeCefuroxime Axetil35$301
Metoprolol Succinate39$283
Methylprednisolone35$264
Amlodipine Besylate46$258
Atorvastatin Calcium29$179
Tamsulosin Hcl23$176
Doxycycline Hyclate20$152
Metoprolol Tartrate37$151
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$149
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav19$137
Prednisone42$135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$99$16,79843 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →